Transforming Cystic Fibrosis Diabetes Screening

Cystic fibrosis diabetes (CFD) or cystic fibrosis-related diabetes (CFRD) is the most common complication of cystic fibrosis in adults, yet timely diagnosis can be challenging. GTT@home from Digostics offers a practical new approach to improve how CFD is identified. The oral glucose tolerance test (OGTT) is the standard test for CFD, as alternative tests for dysglycaemia lack sufficient sensitivity.

By enabling people with cystic fibrosis to carry out their oral glucose tolerance test (OGTT) at home, GTT@home reduces the need for hospital visits, lightens the workload for clinical teams, and helps promote earlier recognition and treatment of CFD.

With regular OGTT screening and appropriate treatment, CFD can be managed successfully, helping people with cystic fibrosis maintain better health and quality of life.

Transforming Cystic Fibrosis Diabetes Screening

Cystic fibrosis diabetes (CFD) or cystic fibrosis-related diabetes (CFRD) is the most common complication of cystic fibrosis in adults, yet timely diagnosis can be challenging. GTT@home from Digostics offers a practical new approach to improve how CFD is identified. The oral glucose tolerance test (OGTT) is the standard test for CFD, as alternative tests for dysglycaemia lack sufficient sensitivity.

By enabling people with cystic fibrosis to carry out their oral glucose tolerance test (OGTT) at home, GTT@home reduces the need for hospital visits, lightens the workload for clinical teams, and helps promote earlier recognition and treatment of CFD.

With regular OGTT screening and appropriate treatment, CFD can be managed successfully, helping people with cystic fibrosis maintain better health and quality of life.

Making the OGTT Easier for People with Cystic Fibrosis

Most clinical bodies recommend screening for CFD using OGTT, as other tests for dysglycaemia lack sufficient sensitivity. However, conventional in-clinic OGTT testing faces two major challenges: low uptake - often 50% or lower - and the risk of exposure to lung infections in clinics and waiting rooms. These factors can lead to delayed or missed diagnoses.

There’s a solution.

The launch of GTT@home has transformed OGTT screening for CFD, allowing patients to complete the test safely at home for the first time. No clinic visits, no waiting rooms, no unnecessary exposure to infections - just a simple, reliable test that fits seamlessly into daily life.

People living with cystic fibrosis can take charge of their health with accurate, convenient diabetes testing designed around their schedules.

At the same time, clinical teams can focus on what matters most - providing high-quality patient care - without the logistical burden of in-clinic OGTT administration.